Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 – Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion


“The Report Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 – Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

Summary

GBI Research, the leading business intelligence provider, has released its latest research, Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion. The currently marketed monoclonal antibodies are clinically and commercially highly successful products in the rheumatoid arthritis market, constituting four of the global top 20 best-selling drugs.

The unique density of monoclonal antibodies that are approved for this indication, significant market exclusivity expiries in the forecast period and yet more monoclonal antibodies in development will change the dynamics in and this highly lucrative market in the forecast period until 2018.

View Report At :http://www.marketresearchreports.biz/analysis/163919

Scope

  • The current therapeutic environment in the treatment of RA across the top seven developed markets, including the US, Germany, France, the UK, Italy, Spain and Japan.

  • Analysis of the competitive environment for monoclonal antibodies with strong data and evidence-based profiling of marketed products, including comparative benchmarking and assessment of efficacy and safety profiles as well as differentiating product features.

  • A detailed pipeline analysis for monoclonal antibodies in rheumatoid arthritis including individual product profiles, a comparative efficacy and safety profile heat map analysis of the most promising pipeline products as well as analyses on the distribution of molecule types across the RA developmental pipeline, the molecular targets of pipeline mAbs and the developmental program types. In addition, detailed analyses of the clinical trial failure rates, the clinical trial durations by phase and clinical trial sizes by participant numbers are provided.

  • Market data on the geographical landscape and therapeutic landscape, including market size, annual cost of therapy, treatment usage patterns such as disease population and prescription populations.

  • Market forecasts across the US, the top five countries in Europe (EU5) Germany, France, the UK, Italy, and Spainas well as Japan. The multiple scenario forecasts take a range of factors that are likely to vary into account and provide a clear perspective on the level of the potential degree of variance in the market sizes.

  • Key market drivers and barriers

  • the major deals that have taken place in the monoclonal antibodies market in rheumatoid arthritis in recent years. Coverage includes Mergers and Acquisitions (M&As) as well as co-development and licensing agreements, which are segmented on the basis of geography and total value. A concomitant analysis of the licensing deal values for products by molecule types and molecular targets is also provided.

Download Sample copy of this Report at:

http://www.marketresearchreports.biz/sample/sample/163919

Reasons to buy

  • Understand the competitive environment for monoclonal antibodies

  • Develop key strategic repositioning initiatives by studying the repositioning trends and strategies of current competitors

  • Understand the clinical and commercial impact of the growing diversification of the molecular targets of monoclonal antibodies in the pipeline and identify potential first-in-class products

  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the RA market in the forecast period

  • Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for monoclonal antibodies in RA

  • Use key benchmark data to forecast costs of developmental programs for monoclonal antibodies in RA by using proprietary clinical trial size and duration analyses

  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps

  • Use proprietary data analyses to assess the market value of pipeline molecules for in-licensing and out-licensing opportunities

Table of Contents

1 Table of Contents

1 Table of Contents 6

1.1 List of Tables 9

1.2 List of Figures 10

2 Introduction 12

2.1 Symptoms 12

2.2 Etiology 13

2.3 Pathophysiology 13

2.3.1 Disease Initiation 13

2.3.2 Disease Propagation 14

2.4 Co-Morbidities and Complications 15

2.5 Diagnosis 16

2.5.1 Physical Examination 16

2.5.2 Blood Tests 16

2.5.3 X-Ray Imaging 17

2.6 Classification 17

2.7 Epidemiology 19

2.8 Prognosis and Disease Staging 19

2.9 Measurement of Treatment Effectiveness 20

2.10 Treatment Options 21

2.10.1 Pharmacological 21

2.10.2 Treatment Algorithms and Prescribing Habits 25

2.10.3 Non-Pharmacological Care 28

3 Marketed Products 29

3.1 Therapeutic Landscape 30

3.1.1 Remicade (infliximab) – Johnson and Johnson, Merck 30

3.1.2 Humira (adalimumab) – Abbott Laboratories 32

3.1.3 Enbrel (etanercept) – Amgen Inc., Pfizer Inc. and Takeda Pharmaceutical Co. Ltd. 34

3.1.4 Rituxan (rituximab) – Genentech (Roche Group), Biogen IDEC Inc. 36

3.1.5 Orencia (abatacept) – Bristol-Myers Squibb 38

3.1.6 Actemra (tocilizumab) -F Hoffman La Roche Ltd. 40

3.1.7 Simponi (golimumab) – Johnson and Johnson, Merck 42

3.1.8 Cimzia (certolizumab pegol) – UCB S.A. 43

3.1.9 Remsima (biosimilar infliximab) – Celltrion Inc. 44

3.2 Comparative Efficacy and Safety 44

3.3 Unmet Need 47

4 Pipeline for Rheumatoid Arthritis Monoclonal Antibody Therapeutics 48

4.1 Overall Pipeline 48

4.2 Molecular Targets in the Pipeline 49

4.3 Clinical Trials 52

4.3.1 Failure Rate 52

4.3.2 Patient Enrolment and Clinical Trial Size 56

4.3.3 Duration 59

4.4 Promising Drug Candidates in the Pipeline 61

4.4.1 Arzerra (ofatumumab) – Genmab A/S, GlaxoSmithKline Plc. 61

4.4.2 LY2127399 (tabalumab) – Eli Lily and Company 61

4.4.3 REGN88 (sarilumab) – Regeneron Pharmaceuticals Inc. 62

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Leave a Reply

Designed by CyFocus.com
Powered by CyFocus.net